These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22467099)

  • 1. Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease.
    Singhal A; Lander E; Karachristos A; Daly E; Dowling P; Patel V; Maloo M; Jain A
    Int J Biol Markers; 2012 Jul; 27(2):e147-51. PubMed ID: 22467099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
    Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
    Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates.
    Deschênes M; Michel RP; Alpert E; Barkun JS; Metrakos P; Tchervenkov J
    Transplantation; 2001 Nov; 72(9):1519-22. PubMed ID: 11707739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.
    Lai YH; Duan WD; Yu Q; Ye S; Xiao NJ; Zhang DX; Huang ZQ; Yang ZY; Dong JH
    World J Gastroenterol; 2015 May; 21(20):6296-303. PubMed ID: 26034365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Significance of Serum Tumor Markers CEA, Ca 19-9, Ca 125, Ca 15-3, and AFP in Patients Scheduled for Orthotopic Liver Transplantation: Do Elevated Levels Really Mean Malignancy?
    Baskiran DY; Sarigoz T; Baskiran A; Yilmaz S
    J Gastrointest Cancer; 2023 Jun; 54(2):442-446. PubMed ID: 35312953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer antigen-125 and ICAM-1 are together responsible for ascites in liver cirrhosis.
    Chowdhury MA; Xiubin Z; Wei H; Chenghao G
    Clin Lab; 2014; 60(4):653-8. PubMed ID: 24779300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.
    Ahn J; Bhuket T; Mosadeghi S; Frenette C; Liu B; Wong RJ
    Hepatol Int; 2016 Sep; 10(5):838-46. PubMed ID: 27221700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of serum and ascites cancer antigen 125 levels in patients with liver cirrhosis.
    Xiao WB; Liu YL
    J Gastroenterol Hepatol; 2003 Nov; 18(11):1315-6. PubMed ID: 14535990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model for end-stage liver disease score versus simplified acute physiology score criteria in acute renal failure after liver transplantation.
    Umbro I; Tinti F; Mordenti M; Rossi M; Ianni S; Pugliese F; Ruberto F; Ginanni Corradini S; Nofroni I; Poli L; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1139-41. PubMed ID: 21620072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of end-stage liver disease and liver transplantation on thyroid hormones.
    Penteado KR; Coelho JC; Parolin MB; Matias JE; Freitas AC
    Arq Gastroenterol; 2015; 52(2):124-8. PubMed ID: 26039830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor biomarkers: help or mislead in the diagnosis of xanthogranulomatous cholecystitis?-analysis of serum CA 19-9, carcinoembryonic antigen, and CA 12-5.
    Yu H; Yu TN; Cai XJ
    Chin Med J (Engl); 2013 Aug; 126(16):3044-7. PubMed ID: 23981609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
    Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
    Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
    Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
    Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
    Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
    Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt.
    Ahmed R; Santhanam P; Rayyan Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1226-7. PubMed ID: 26111072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer antigen 125 in patients with chronic liver disease.
    Devarbhavi H; Kaese D; Williams AW; Rakela J; Klee GG; Kamath PS
    Mayo Clin Proc; 2002 Jun; 77(6):538-41. PubMed ID: 12059123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.
    Hong YF; Chen ZH; Ma XK; Li X; Wu DH; Chen J; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Wen JY; Lin Q; Jia CC; Wu XY
    Tumour Biol; 2016 Apr; 37(4):5265-73. PubMed ID: 26561464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.